TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin treatment […]

Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC50=50 nM). Tpl2 consists of COT kinase and MAP3K8. Tpl2 Kinase Inhibitor 1 plays an important role in the regulation of the inflammatory response and the progression of some cancers[2].IC50 & Target:Tpl2/COT kinase/MAP3K8In Vitro:Tpl2 (Cot/MAP3K8) is a serine/threonine kinase in the […]

TPP-1 is a potent inhibitor of the?PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.In Vitro: TPP-1 binds to PD-L1 with high affinity and blocks PD-1/PD-L1 interaction.?The?KD?value of PD-L1 with TPP-1 peptide is about 95 nmol/L (around five times less […]

TPPS dihydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

TPPS can be used as a non-cytotoxic probe for detecting tumor location.In Vitro: TPPS (0-20 μg/mL) shows no toxicity in Vero and HEp-2 cells in vitro and predominantly locates in the soluble and protein fractions in cells.In Vivo: TPPS4 shows the highest tumor to tissue ratios after 96 hours injection with a dose dependent manner[2].TPPS4 […]

TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain.IC50 & Target: nAChRIn Vivo: TQS (1 or 4 mg/kg; i.p.) reduces the expression of LPS-induced IκB mRNA, CD11b mRNA and regulates microglial morphological changes in the hippocampus.

Tr-PEG8-OH is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Tr-PEG8-OH is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.In Vitro: ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.PROTACs contain two different ligands connected by […]

Trabectedin D3 (Ecteinascidin 743 D3) is deuterium labeled Trabectedin. Trabectedin is a tetrahydroisoquinoline alkaloid with potent antitumor activity. Trabectedin binds to the minor groove of DNA, blocks transcription of stress-induced proteins, induces DNA backbone cleavage and cancer cells apoptosis, and increases the generation of ROS in MCF-7 and MDA-MB-453 cells. Trabectedin has tje potential for […]

Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma.In Vitro: Trabodenoson treatment significantly increaseS MMP-2 activity and MMP-14 abundance, while decreasing fibronectin and collagen IV expression.In Vivo: Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg […]

Tracazolate (ICI 136753) hydrochloride is a potent GABAA receptor modulator. Tracazolate hydrochloride has selectivity for β3 and potentiates α1β1γ2s (EC50=13.2 μM), α1β3γ2 (EC50=1.5 μM). Tracazolate hydrochloride has the potency (EC50) determined by the nature of the third subunit (γ1-3, δ, ε) within the receptor complex. Tracazolate hydrochloride possesses anxiolytic and anticonvulsant activity[2].IC50 & Target: GABAAIn […]

TRAF-STOP inhibitor 6877002, is a selective inhibitor of CD40-TRAF6 interaction, compound VII, shows inhibition of NF-κB activation in RAW cells, extracted from patent WO2014033122A1. TRAF-STOP 6877002 prevents the progression of established atherosclerosis in mice, reduces leukocyte recruitment and reduces macrophage activation; reduces macrophage proliferation in atherosclerotic plaques[2].IC50 & Target: CD40-TRAF6 interaction; NF-κB

Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD).